TradeWell Research · November 3, 2026
DRUG fell 52.3%: a research read on the day's mover
moversanalyzedaily
Quick answer
Bright Minds Biosciences fell 52.3% in the 2026-11-02 session. On the 2026-11-04 scan, the newest published, its free 1Y TW Quant Score is 67.9 (rank 1,340 of 4,167), against 16.6 (rank 3,477 of 4,169) on the 2026-11-02 scan. The experimental levels card lists no support below the $23.00 close of 2026-11-06 and its nearest resistance at $36.67. The next report is dated 2026-12-22.
Bright Minds Biosciences Inc. (DRUG) fell 52.3% in the session of 2026-11-02 (daily bars, as of 2026-11-02), one of the largest moves among ranked names that day. This note was drafted on 2026-11-03 from the 2026-11-02 scan. It is published with every TradeWell figure refreshed to the newest published scan; the move itself is a historical fact and is not restated.
TradeWell scores and ranks below are as of the 2026-11-04 scan, on the free 1-year view, the same numbers a visitor sees without a subscription. As read on 2026-11-08, the API marks that scan as the newest published: its staleness notice says the data is two trading sessions behind the 2026-11-06 close and that newer rankings have not been published yet. Nothing below is from a later scan.
What changed since the 2026-11-02 scan
On the 2026-11-02 scan, the first scan after the fall, DRUG carried a 1Y TW Quant Score of 16.6 and a 1Y rank of 3,477 of 4,169. On the 2026-11-04 scan it carries 67.9 (rank 1,340 of 4,167). The scan does not say why the ranking moved, and a shift of more than two thousand places across two scans is a reason to open the stock page and read its signal breakdown rather than to treat either number as settled. The sector rank went the other way as a data point: it read 451 within Healthcare on the 2026-11-02 scan, and the stock page serves no sector rank for DRUG on the 2026-11-04 scan, so it is MISSING below rather than a number.
What moved, and where it sits
- Sector: Healthcare, industry: Biotechnology.
- 1Y TW Quant Score 67.9, 1Y rank 1,340 of 4,167, as of the 2026-11-04 scan.
- Sector rank: MISSING within Healthcare, as of the 2026-11-04 scan (the stock page returns no sector rank for DRUG on this scan; it returned 451 on the 2026-11-02 scan).
Levels
The experimental levels card, read as of 2026-11-06 (5-year daily bars, not yet validated), puts the last close at $23.00. It lists no support level below that close, so the nearest support is MISSING rather than a number, and the nearest resistance above it is $36.67. On the 2026-11-02 read, the card showed support at $25.30 and the same $36.67 resistance; the $25.30 level is no longer on its support list, and the 2026-11-06 close of $23.00 is below it. The MACD and setup read is part of the paid screener and is not shown here.
Earnings inside a horizon
The next report is dated 2026-12-22, unchanged since the draft. It falls inside these horizon windows counted from 2026-11-04: 3-month, 6-month, 1-year, 3-year, 5-year. It sits outside the 1-day, 3-day, 1-week, 2-week and 1-month windows. A ranking says nothing about how a stock reacts to its report.
Biotechnology peers
These three Biotechnology names are the peers the DRUG stock page listed on the 2026-11-02 scan. The peer panel is recomputed each scan, so the scores and ranks below are each company's own, read from its stock page as of the 2026-11-04 scan, with the 2026-11-02 scan score alongside.
| Ticker | Company | 1Y score (2026-11-04 scan) | 1Y rank (of 4,167) | 1Y score (2026-11-02 scan) |
| REGN | Regeneron Pharmaceuticals, Inc. | 48.0 | 2,168 | 29.9 |
| REPL | Replimune Group, Inc. | 76.9 | 962 | 30.9 |
| EXEL | Exelixis, Inc. | 84.3 | 653 | 19.2 |
Peer scores are as of the 2026-11-04 scan. All four names in this note score higher on the 2026-11-04 scan than on the 2026-11-02 scan. A shift shared across a group of Biotechnology names is worth reading as a property of the scan as much as of any one company, and the stock pages show which signals moved.
Prediction pages: REGN.
How to read these numbers
A one-day move and a 1-year rank measure different things. The move is a fact about one session; the rank is a relative ordering of 4,167 names under the 1-year model on one scan, and it changes from scan to scan as the inputs change. The 1-year model currently carries an at-risk health notice on the site: its expected return is to be read as a range, not a point, and the notice says scores and rankings are unaffected by that caveat. Each stock page shows the scan date next to the score, the free 1-year view, and the other horizons for subscribers.
What this note claims
A TradeWell rank is a relative ordering under a stated model, for a stated horizon, on a stated scan. It is not a forecast that a price will rise, and it is not tailored to anyone's situation. See how accuracy is measured and the methodology.
Not investment advice.
Not investment advice. TradeWell Research LLC publishes research software and notes for informational purposes only. Nothing here is a recommendation to buy or sell any security.
Related research
Prediction pages: REGN stock prediction
Live rankings: TradeWell dashboard.
More: research library · methodology · stock screener by time horizon.